Multiple adjusted response analysis after 1 year of treatment with a first TNFi
| Multiple adjusted analysis for treatment response | Response rates in different patient subgroups | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current smokers vs non-smokers | Past smokers vs non-smokers | Patients with positive predictors of good response* | Patients with negative predictors of good response* | |||||||||
| Smoking status | OR | 95% CI | p Value | OR | 95% CI | p Value | Current smokers (%) | Past smokers (%) | Non-smokers (%) | Current smokers (%) | Previous smokers (%) | Non-smokers (%) |
| BASDAI50 | 0.54 | 0.31 to 0.95 | 0.03 | 0.66 | 0.35 to 1.24 | 0.19 | 59 | 63 | 73 | 15 | 18 | 24 |
| ASDAS-MI | 0.43 | 0.23 to 0.82 | 0.01 | 0.79 | 0.38 to 1.63 | 0.53 | 41 | 56 | 62 | 7 | 12 | 15 |
| ASAS40 | 0.43 | 0.24 to 0.76 | 0.004 | 0.81 | 0.42 to 1.55 | 0.52 | 52 | 68 | 72 | 11 | 19 | 23 |
Multiple adjusted analysis for treatment responses to TNF inhibitors for current or previous smokers versus non-smokers.
*Response rates are calculated based on multiple adjusted models for patients of average age, body mass index, educational level and baseline Bath Ankylosing Spondylitis Functional Index in subgroups of patients in the presence or absence of the following positive predictors of good response (male sex, elevated baseline CRP, human leucocyte antigen-B27 positivity, classification as ankylosing spondylitis, regular physical exercise). Models are based on 317, 293 and 319 patients for BASDAI50, ASDAS-MI and ASAS40 respectively.
ASAS40, Assessment in Spondyloarthritis international Society criteria for 40% improvement; ASDAS-MI, Major Improvement in the Ankylosing Spondylitis Disease Activity Score; BASDAI50, 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; TNFi, tumour necrosis factor inhibitor.